Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD178 Purified

Anti-Hu CD178 Purified

Regulatory status

RUO

Antigen

CD178

Clone

NOK-1

Format

Purified

Reactivity

Human

Application

IP, WB, FC (QC tested), ICC

Variant

0.1 mg

11-754-C100

In stock

143.00 USD

0.025 mg

11-754-C025

Delivery 1 week

71.50 USD

Variant

0.1 mg

11-754-C100

In stock

143.00 USD

0.025 mg

11-754-C025

Delivery 1 week

71.50 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody NOK-1 recognizes an extracellular epitope of CD178 / Fas-L, an approximately 40 kDa transmembrane glycoprotein expressed on neutrophils, monocytes, and activated T and NK cells.

Workshop

HLDA VII: 70322

Application

IP, WB, FC (QC tested), ICC

Application details

Flow cytometry: Recommended dilution: 1-4 µg/ml

Reactivity

Human

Immunogen

L5178Y mouse T lymphoma cells expressing recombinant human CD178

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

APTL, FASL, FAS-ligand, CD95L, TNFSF6, TNLG1A

Antigen description

CD178 / Fas-L (Fas ligand, CD95L), a member of TNF family transmembrane glycoproteins, is responsible for induction of apoptosis in cells containing its receptor CD95 / Fas. The CD178-mediated apoptosis pathway has been implicated in peripheral tolerance, tissue pathology, and maintenance of the immune privileged sites. Defects in this interaction may be related to some cases of systemic lupus erythematosus (SLE). CD178 was also described as a co-stimulatory receptor for T-cell activation in mice in vivo.

Entrez Gene ID 356

UniProt ID P48023

Flow cytometry surface staining pattern of FasL transfected L5178Y cells stained using anti-human CD178 (NOK-1) purified antibody (concentration in sample 9 μg/ml) GAM APC.

Separation of FasL transfected L5178Y cells stained using anti-human CD178 (NOK-1) purified antibody (concentration in sample 9 μg/ml, GAM APC, red-filled) from FasL transfected L5178Y cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).

Product specific references:

Ji J, Chen JJ, Braciale VL, Cloyd MW: Apoptosis induced in HIV-1-exposed, resting CD4+ T cells subsequent to signaling through homing receptors is Fas/Fas ligand-mediated. J Leukoc Biol. 2007 Jan;81(1):297-305.
PubMed

Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995 Dec 1;182(6):1777-83.
PubMed

Jodo S, Pidiyar VJ, Xiao S, Furusaki A, Sharma R, Koike T, Ju ST: Fas ligand (CD178) cytoplasmic tail is a positive regulator of Fas ligand-mediated cytotoxicity. J Immunol. 2005 Apr 15;174(8):4470-4.
PubMed

Ghadimi MP, Sanzenbacher R, Thiede B, Wenzel J, Jing Q, Plomann M, Borkhardt A, Kabelitz D, Janssen O: Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178). FEBS Lett. 2002 May 22;519(1-3):50-8.
PubMed

Chopin D, Barei-Moniri R, Maillé P, Le Frère-Belda MA, Muscatelli-Groux B, Merendino N, Lecerf L, Stoppacciaro A, Velotti F: Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol. 2003 Apr;162(4):1139-49.
PubMed